{"id":"vonoprazan-amoxicillin-and-levofloxacin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vonoprazan works by competitively inhibiting the H+/K+ ATPase enzyme in the parietal cells of the stomach, which leads to a decrease in gastric acid secretion. This results in a reduction in the symptoms of gastroesophageal reflux disease (GERD) and peptic ulcer disease. Additionally, vonoprazan has been shown to have a rapid onset of action and a long duration of effect, making it a useful treatment option for patients with GERD and peptic ulcer disease.","oneSentence":"Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by blocking the H+/K+ ATPase enzyme in the parietal cells of the stomach.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:54.199Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of gastroesophageal reflux disease (GERD)"},{"name":"Treatment of peptic ulcer disease"}]},"trialDetails":[{"nctId":"NCT07179159","phase":"NA","title":"Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial","status":"RECRUITING","sponsor":"Yanqing Li","startDate":"2025-09-09","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":372},{"nctId":"NCT07344506","phase":"PHASE4","title":"CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2025-05-01","conditions":"H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate","enrollment":942},{"nctId":"NCT07040839","phase":"PHASE4","title":"Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-07","conditions":"H Pylori","enrollment":128},{"nctId":"NCT06414707","phase":"PHASE3","title":"Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-10-12","conditions":"Helicobacter Pylori Infection","enrollment":320},{"nctId":"NCT06101420","phase":"PHASE3","title":"Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":"Helicobacter Pylori Eradication","enrollment":232},{"nctId":"NCT05173493","phase":"","title":"The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-12-30","conditions":"Helicobacter Pylori Infection","enrollment":670},{"nctId":"NCT04810793","phase":"","title":"The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure","status":"COMPLETED","sponsor":"Shandong University","startDate":"2020-07-01","conditions":"Helicobacter Pylori","enrollment":820},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04991584","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-08-04","conditions":"Helicobacter Pylori Infection","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vonaspire 20 mg","Amoxil 1 gm","Tavanic 500 mg"],"phase":"phase_3","status":"active","brandName":"Vonoprazan, Amoxicillin and Levofloxacin","genericName":"Vonoprazan, Amoxicillin and Levofloxacin","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by blocking the H+/K+ ATPase enzyme in the parietal cells of the stomach. Used for Treatment of gastroesophageal reflux disease (GERD), Treatment of peptic ulcer disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}